Events for “apy”

Best CD rates today, Wednesday, August 26, 2026: Earn up to 4.30% APY

Best high-yield savings interest rates today, Wednesday, August 26, 2026: Earn up to 4.15% APY

Best CD rates today, Tuesday, August 25, 2026: Lock in up to 4.30% APY today with multiple offers

This 15-Foot Python Is the First Known Snake to Receive Electrochemotherapy for Cancer. Now, She's Officially Free of the Disease

The pioneering treatment makes it easier for traditional chemotherapy drugs to penetrate cancer cells. After the procedure, the reptile, named Jodie Foster, made a speedy recovery

STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns

The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.

STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more

President Trump’s pledge to make pricey weight loss drugs widely available for low-income Americans through Medicaid is not panning out

Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?

Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation.

When Vocabulary Comprehension Fails Clinical Reasoning: Evaluating Therapy Bots' Safety Risks for Generation Alpha

arXiv:2608.20345v1 Announce Type: new Abstract: Conversational AI systems have become informal mental health support resources for Generation Alpha (Gen Alpha, born 2010-2024), with 13.1% of U.S. adolescents (5.4 million) using generative AI for mental health advice. While these

Accordia Bank is offering a 5.00% APY booster on high-yield savings account for its rebrand — how to get it

Utah residents can snag a 5.00% APY boost as Accordia Bank celebrates its rebrand, while everyone else can still earn a competitive rate.

Best high-yield savings interest rates today, Monday, August 24, 2026: Earn up to 4.15% APY

STAT+: FDA approves Ultragenyx gene therapy

Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout

STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more

A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort

Best CD rates today, Sunday, August 23, 2026: Lock in up to 4.35% APY

Best CD rates today, Monday, August 24, 2026: Lock in up to 4.35% APY

Best CD rates today, Saturday, August 22, 2026: Best CD account earns 4.35% APY

Doctors achieve new feat in cancer treatment with cord transplant and Car T-cell therapy

Doctors at Narayana Health have reported two medical breakthroughs: a seven-year-old thalassaemia patient is now transfusion-free after a Haplo-cord transplant, while a 62-year-old brain cancer patient responded to dual-target CAR-T cell therapy

In ‘Fires in the Dark,’ Kay Redfield Jamison Turns to Healers

In “Fires in the Dark,” Jamison, known for her expertise on manic depression, delves into the quest to heal. Her new book, she says, is a “love song to psychotherapy.”

The brain struggles to make new neurons in people with depression

Nature, Published online: 25 August 2026; doi:10.1038/d41586-026-02661-8 High resolution, wide-coverage map of the hippocampus reveals possible pathways for therapy.

Spiraling health costs force Iranians to delay care

A single chemotherapy session in Iran can cost six times the monthly minimum wage. As drug prices soar and medicine is in short supply, doctors say more patients are delaying or abandoning treatment.

Scientists deploy Merck’s Ebola vaccine in DRC

Prostate cancer therapy, Meta glasses in hospital settings, and more health news from Morning Rounds

London Zoo animals hop on scales for weigh-in

Kiwi the Capybara is among animals getting their annual health check while data is gathered and shared.

Iran's medicine crisis prices patients out of treatment

A single chemotherapy session in Iran can cost six times the monthly minimum wage. As drug prices soar and medicine shortages persist, doctors say more patients are delaying or abandoning treatment they cannot afford.

STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection

Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.